Provided by Tiger Trade Technology Pte. Ltd.

PharmaCyte Biotech, Inc.

0.5396
+0.01462.78%
Post-market: 0.5294-0.0102-1.89%17:34 EDT
Volume:64.81K
Turnover:34.34K
Market Cap:5.79M
PE:-0.19
High:0.5399
Open:0.5200
Low:0.5110
Close:0.5250
52wk High:1.51
52wk Low:0.5043
Shares:10.74M
Float Shares:9.96M
Volume Ratio:0.61
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7700
EPS(LYR):-2.7700
ROE:-44.72%
ROA:-6.51%
PB:0.17
PE(LYR):-0.19

Loading ...

May 30, 2023

Correspondence

Form CORRESP - Correspondence
May 19, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 12, 2023

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
May 11, 2023

Major Issues Report

8-K - Current report
Mar 16, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 02, 2023

Major Issues Report

8-K - Current report
Dec 30, 2022

Major Issues Report

8-K - Current report
Dec 14, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 18, 2022

Major Issues Report

8-K - Current report
Nov 07, 2022

Major Issues Report

8-K - Current report
Oct 20, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Oct 14, 2022

Major Issues Report

8-K - Current report
Oct 07, 2022

Major Issues Report

8-K - Current report
Sep 14, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 16, 2022

Major Issues Report

8-K - Current report
Aug 15, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jul 28, 2022

Major Issues Report

8-K - Current report
Jul 28, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]